Here are the latest stories being discussed in biopharma today:

AbbVie signs $1.9B deal with Medincell for injectable platform
AbbVie is investing around $1.9 billion in a long-acting injectable technology developed by French biotech Medincell. Initially, Medincell will receive a $35 million upfront payment and could potentially earn up to $1.9 billion in milestones for the development of up to six therapeutic long-acting products, spanning various therapeutic areas and indications.

Sandoz’s Humira biosimilar gains momentum thanks to CVS partnership
Sandoz and CVS have collaborated to push the AbbVie Humira biosimilar Hyrimoz further into the market, aiding in its significant growth in market share. As of April 1, brand-name Humira has been removed from CVS’s major national formularies, which influences around 30 million people, and replaced with Hyrimoz.

J&J’s multiple myeloma therapies driving oncology business
J&J have announced that their multiple myeloma therapies are propelling the company’s oncology business forward, despite the slower-than-expected sales of Carvykti. First-quarter sales of Carvykti reached $157 million, slightly down on last year’s fourth-quarter sales of $159 million.

FDA issues warning to Natco over Indian facility
The FDA has warned pharmaceutical manufacturer Natco about violations at its facility in Telangana, India. The company has now suspended productions for US shipment until they can prove the issues raised by the FDA have been addressed.

Drugmakers face pressure for injection pen recycling
As the demand for injection pens in the treatment of obesity and diabetes increases, manufacturers like Novo Nordisk are being pressured to focus more on recycling the discarded single-use pens.

Senate bill targeting WuXi won’t affect federal spending, says CBO
The Congressional Budget Office (CBO) has claimed that the Senate’s bill aiming to blacklist Chinese biotech firms like WuXi AppTec from working within the US will not have an impact on federal debt.